Moreover, depletion of galectin-3 expression by siRNA enhances sensitivity of ovarian cancer cells to paclitaxel (in SK-OV-3 cells) [5, 25] and cisplatin [15], as well osteosarcoma cells to cisplatin [14], pancreatic cancer cells to cisplatin and gemcitabine [16], cholangiocarcinoma cells to cisplatin and 5-FU [18], anaplastic thyroid carcinoma cells to cisplatin [40], and prostate cancer to cisplatin [41]. This evidence concerns the gene LGALS3 and osteosarcoma.